DBIBB
- CAS No.
- 1569309-92-7
- Chemical Name:
- DBIBB
- Synonyms
- DBIBB;Benzoic acid, 2-[[[4-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)butyl]amino]sulfonyl]-
- CBNumber:
- CB33152600
- Molecular Formula:
- C23H20N2O6S
- Molecular Weight:
- 452.48
- MDL Number:
- MOL File:
- 1569309-92-7.mol
DBIBB price More Price(9)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 17529 | DBIBB ≥98% | 1569309-92-7 | 1mg | $57 | 2024-03-01 | Buy |
| Cayman Chemical | 17529 | DBIBB ≥98% | 1569309-92-7 | 5mg | $220 | 2024-03-01 | Buy |
| Cayman Chemical | 17529 | DBIBB ≥98% | 1569309-92-7 | 10mg | $302 | 2024-03-01 | Buy |
| Usbiological | 445823 | DBIBB | 1569309-92-7 | 1mg | $319 | 2021-12-16 | Buy |
| TRC | D194975 | DBIBB | 1569309-92-7 | 10mg | $265 | 2021-12-16 | Buy |
DBIBB Chemical Properties,Uses,Production
Uses
DBIBB is a non-lipid agonist of LPA2 (lysophosphatidic acid receptor 2), protecting rat intestinal crpyt epithelium-like IEC-6 cells against caspase 3/7 activation and apoptosis.
Biological Activity
dbibb, a butylsulfamoyl benzoic acid analog, is a non-lipid agonist of lpa2 with an ec50 of 0.10 μm. dbibb has no effect at other lpa receptor subtypes [1]. the bioactive phospholipid lysophosphatidic acid (lpa) has been involved in stimulating cell proliferation, migration and survival by acting on its cognate g-protein-coupled receptors. aberrant lpa production, receptor expression and signalling probably contribute to cancer initiation, progression and metastasis [2].
in vitro
dbibb treatment postirradiation significantly (p< 0.01) increased the clonogenic survival of iec-6 cells in the 2-6 gy dose range. dbibb reduced dna fragmentation 4hr after irradiation in a dose dependent manner. dbibb also reduced caspase 3/7 activity and dna fragmentation in lpa2mef treated with adriamycin. in purified cd34+ progenitor cells, dbibb significantly increased the total number of colonies and specifically enhanced the survival of the granulocyte/macrophage lineages [1].
in vivo
using a murine gi-ars mice model of partial-body irradiation (pbi) with shielding of the bone marrow contained in the tibiae, fibulae, and paws, administrations of up to 10 mg/kg of dbibb for 10 days showed no visually observable adverse effects and pathological findings at necropsy, indicating the lack of toxicity. the group that received 10 mg/kg dbibb showed a significant increase in survival. in c57bl/6 mice, dbibb showed a dose-dependent increase in the number of surviving crypts compared with the vehicle control [1].
References
[1] patil r, szabó e, fells j i, et al. combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an lpa 2 receptor-specific nonlipid agonist[j]. chemistry & biology, 2015, 22(2): 206-216.
[2] mills g b, moolenaar w h. the emerging role of lysophosphatidic acid in cancer[j]. nature reviews cancer, 2003, 3(8): 582-591.
DBIBB Preparation Products And Raw materials
Raw materials
Preparation Products
DBIBB Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ChemStrong Scientific Co.,Ltd | 0755-0755-66853366 13670046396 | sales@chem-strong.com | China | 18018 | 56 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 | info@efebio.com | China | 9708 | 58 |
| ChemeGen(Shanghai) Biotechnology Co.,Ltd. | 18818260767 | sales@chemegen.com | China | 11289 | 58 |
| Energy Chemical | 021-58432009 400-005-6266 | marketing1@energy-chemical.com | China | 44843 | 58 |
| Changzhou Furuisi Biotechnology Co., Ltd | 0519-85524369 | 3477467573@qq.com | China | 8618 | 58 |
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 24017 | 58 |
| Nantong Hanfang Biotechnology Co. , Ltd. | 18616537568 | hanfangpharma@126.com | China | 30968 | 58 |
| RD International Technology Co., Limited | 18024082417 | market@ubiochem.com | China | 9155 | 58 |
| ApexBio Technology | -- | sales@apexbt.com | United States | 6254 | 58 |